CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE

Their core work

CHU Toulouse is one of France's largest university hospitals, combining clinical care with translational research across multiple medical specialties. In H2020, they contribute clinical expertise, patient cohorts, and trial infrastructure to European health research — particularly in neurodegenerative diseases, regenerative medicine, and ophthalmology. Their role is typically as a clinical site providing real-world patient data, biobank access, and medical validation within large multi-center studies. They bridge the gap between laboratory research and bedside application, making them a valuable partner for projects that need clinical validation.

What they specialise in

How they've shifted over time

In 2015-2018, CHU Toulouse focused heavily on regenerative medicine and advanced therapies — stem cell treatments for stroke and osteoarthritis, amyloid imaging for Alzheimer's, and thyroid disease prevention. From 2019 onward, their portfolio shifted toward digital health interventions (mHealth for dementia prevention, AI-driven speech assessment), gene therapy (lymphedema), and large-scale pharmacovigilance (medication safety in pregnancy). The evolution shows a hospital moving from being primarily a clinical trial site for biological therapies toward integrating digital tools and precision medicine approaches.

CHU Toulouse is expanding from traditional clinical trial participation into digital health, mHealth, and gene therapy — signaling readiness for projects combining clinical data with digital intervention platforms.

How they like to work

CHU Toulouse consistently operates as a clinical partner rather than a project leader — zero coordinator roles across all 9 projects, always joining as participant or third party. They work in large consortia (179 unique partners across 33 countries), which is typical for major university hospitals that provide clinical sites and patient access within multi-center European studies. This makes them a reliable, low-risk partner who brings clinical infrastructure without competing for project leadership.

With 179 unique consortium partners across 33 countries, CHU Toulouse has one of the broadest collaborative networks among French university hospitals in H2020. Their partnerships span nearly all EU member states, reflecting the multi-center clinical trial model that dominates health research.

What sets them apart

CHU Toulouse combines the clinical scale of a major French university hospital (one of the largest in France) with diverse therapeutic expertise spanning neurology, ophthalmology, regenerative medicine, and gene therapy. Unlike single-specialty research centers, they can provide clinical validation across multiple disease areas within one institution. Their consistent role as a clinical partner — never coordinator — means they are experienced at integrating into existing project structures without adding governance complexity.

Highlights from their portfolio

• AMYPAD
  Largest single funding (EUR 1.06M) — a flagship Alzheimer's prevention project using amyloid PET imaging across Europe, part of the IMI initiative.
• TheraLymph
  Most recent project (2020) with EUR 947K funding, representing their move into gene therapy for lymphedema — a relatively underserved condition with high unmet medical need.
• ConcePTION
  EUR 913K for building a pharmacovigilance ecosystem for pregnancy — a critical safety domain where large hospital databases are essential for meaningful surveillance.